ASCELIA

AN ONCOLOGY-DEDICATED DRUG DEVELOPMENT COMPANY

Ascelia Pharma is listed on Nasdaq Stockholm main market (small cap) under the ticker ACE

Lead candidate Mangoral (phase III ready) is an MRI imaging drug being developed for detection and localization of liver metastases.

Oncoral (phase II ready) is a novel tablet-based irinotecan formulation, intended for treatment of advanced gastric (stomach) cancer.

• 2019-04-12Exercise of over-allotment option, stabilisation notice and end of the stabilisation period
• 2019-04-11Stabilisation notice
• 2019-04-08Encouraging results from the Phase I combination study with Oncoral and oral capecitabine published in the journal Cancer Chemotherapy and Pharmacology